Navigation Links
Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
Date:7/15/2011

LOS ANGELES, July 15, 2011 /PRNewswire/ -- The current issue of Popular Science magazine includes a feature story profiling William H. Andrews, a member of the Genesis Biopharma, Inc. (OTC/BB: GNBP) Board of Directors, and his work on the anti-aging properties of the human telomerase gene.

The entire 11-page story, titled "The Man Who Would Stop Time" by Joseph Hooper, can be found at www.popsci.com

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged in the development of targeted cancer therapies. For more information about the company, visit www.genesis-biopharma.com.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
2. Genesis Biopharma Conference Call and Webcast Reminder
3. Genesis Biosciences Receives Pulire Innovation Award for e card Sanitary Bin Treatment Product
4. Patrick Hwu, M.D., and Mario Sznol, M.D., Join Genesis Biopharmas Scientific and Medical Advisory Board
5. Governor Gray Davis Joins Genesis Biopharma as Chairman of Corporate Advisory Board
6. ThermoGenesis Announces China Customer Implements Cord Blood Products
7. Tissue Genesis Begins FDA-Approved Clinical Trial
8. CryoLife Amends Tender Offer Related to its Proposed Acquisition of Cardiogenesis Corporation
9. Organogenesis, Life Sciences Center Break Ground on Worlds Largest Automated Living Cell Manufacturing Plant
10. Announcing ValGenesis On-Demand SaaS Solution
11. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):